Stock ROIV ROIVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
11.03 USD +1.38% Intraday chart for Roivant Sciences Ltd. +5.45% -1.78%
04-05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
04-04 Moderna Suffers Setback in Lawsuit by Arbutus MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROIVANT SCIENCES LTD. Stock Roivant Sciences Ltd.
-1.78% 8.89B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. Ratings Roivant Sciences Ltd.